Even greater challenges lie around the corner. Over the next 10 to 20 years, scientists and clinicians will learn more and more about the genetic makeup of groups and individuals; therefore, there will be greater pressure to tailor drug and other therapies to the genetic profile of an individual patient. Today, in Canada alone, more than 500 biotechnology companies are working on various types of genetic research and related product development. The next tsunami of demand for enhanced expenditure on drug treatments will undoubtedly feature the demand for therapies that are increasingly individualized. buy asthma inhalers
The debate about the necessary professional and political environments to support progress on optimal drug therapy is unlikely to be brief. We will continue to see the fruits of our scientific labours presented in the form of better curative and preventive therapies, and we will need to hone our decisionmaking abilities in order to ensure that maximum health benefits from pharmacotherapy are obtained for as many citizens as possible. There will be a demand for rigorous scientific investigation, not just about the utility of new agents but also about the impact of health policy changes on outcomes. It is encouraging that the various stakeholders committed to the ideal of improved drug therapy are increasingly seen to be espousing parallel initiatives. The sponsors of the November 1999 meeting are eager to further this important debate and current plans call for a national roundtable to be held in January 2001. We look forward to sharing the results of those discussions with a broad audience wishing to improve drug therapy for all Canadians.